By

Riham Hazem RaafatLecturer of Chest Diseases

Ainshams University

Pulmonary Emboli originate::

-Deep venous system of

the lower extremities (90-95%)

-Uterine and prostatic veins

-Upper extremities

-Renal veins

-Right side of the heart

Risk Factors

• Alteration of blood flow: – Prolonged immobilisation, – Obesity, – Pregnancy, – Cancer

• Factors in blood vessel wall: – Surgery (risk in 1st 2 wks up to 3 Ms), – Catheterisation,– Trauma

• Hypercoagulable states: – Estrogen containing OCP, – Genetic thrombophilia (Factor V Leiden deficiency, Protein C and

Protein S deficiency, antithrombin III deficiency etc.), – Acquired thrombophilia (antiphospholipid syndrome, nephrotic

syndrome, paroxysmal nocturnal hemoglobinuria)

What is PE?

- A pulmonary embolism refers to the obstruction of

a pulmonary artery or its branches

Incidence: 600,000/year

Mortality rate: 50,000 to 200,000/yr

Non-Thrombotic pulmonary embolismNon-Thrombotic pulmonary embolism• Septic embolism- drug addicts, catheters & pacemaker wires,

septic thrombophlebitis staph, anaerobes, G-ve Abs

• Intravascular foreign bodies- broken catheters, guide wires,

vena cava filters, coils, silicone removed as sepsis + Throm

• Fat embolism- trauma, after liposuction, lipid infusion PE,

ARDS (distress, peticheal rash, altered mental status in 12-36hrs)

self limiting +/- high dose steroids

• Air embolism- venous >, 100-500ml fatal Lt.Lat., 100% O2

• Amniotic fluid embolism- occur in 1/8000 – 1/80,000, high

maternal (21%) & fetal mortality PE, ARDS supportive

• Tumor embolism treat underlying tumor

PathophysiologyPathophysiology

• Increased pulmonary vascular resistance

• Impaired gas exchange

• Alveolar hyperventilation

• Increased airway resistance

• Decreased pulmonary compliance

• More than 50% of the vascular bed has to be

occluded before PAP becomes substantially

elevated

• When obstruction approaches 75%, the RV must

generate systolic pressure in excess of 50 mmHg to

preserve pulmonary circulation

• The normal RV is unable to accomplish this acutely

and eventually fails

Clinical PresentationClinical Presentation The Classic Triad: Occurs in < 20% of patients

Hemoptysis, Dyspnea, Chest Pain

Clinical Presentations:

• Massive Embolism or high risk PE: Acute PE with

obstructive shock or SBP <90 mmHg for > 15 minutes

• Submassive Embolism or intermediate risk PE: Acute

PE without systemic hypotension (SBP ≥90 mm Hg) but with

either RV dysfunction or myocardial necrosis

• Non-massive or low risk PE: None of the above severe

features.

Pleuritic (Infarction)

Central (RV ischemia)

• Submassive PE, angiographically defined blockage of flow to an

area served by less than two lobar arteries. These patients have

acute or unexplained dyspnea with exertion or at rest. So, they

can be easily confused with infection, asthma, CHF

• Massive PE, or a clot which obstructs two lobar arteries, so-called

“Saddle Embolus”. These patients have acute corpulmonale

often with syncope. You might think there having an MI or look

septic!

• Pulmonary infarction, may have pleuritic chest pain and can be hard to distinguish between that patient with infection pneumonitis

Symptom Percent

Dyspnea 84

Chest Pain, pleuritic 74

Anxiety 59

Cough 53

Hemoptysis 30

Sweating 27

Chest Pain, non-pleuritic 14

Syncope 13

Sign Percent

Tachypnea > 20/min 92

Rales 58

Accentuated S2 53

Tachycardia >100/min 44

Fever > 37.8 43

Diaphoresis 36

S3 or S4 gallop 34

Thrombophlebitis 32

Lower extremity edema 24

Diagnosis

• Risk stratification

• Clinical examination

• Bed side tests (ECG, ABG)

• Laboratory tests (D-dimer, Cardiac biomarkers)

• Imaging techniques (Ultrasound/ Doppler scan, CXR, CTPA, V/Q scan, Echocardiogram)

Risk stratification

• PERC Rule

• Wells score for PE

• Modified Geneva score for PE

• PESI Index

PERC

Wells score for PE

3 Level Score 2 Level Score

Original Geneva scoreOriginal Geneva score

Revised Geneva scoreRevised Geneva score

Pulmonary Embolism Severity Index (PESI)

PESI to differentiate Int from Low

Risk

Biomarkers (cardiac & non-cardiac)• Troponin ‐ released from right ventricle Injury

• Cardiac BNP ‐ released from cardiac myocytes in response

to elevated pressures RVD

*A normal troponin and BNP can safely exclude high risk

patients with a negative predictive value of 97-100%

• H-FABP (heart type fatty acid binding protein) – early

marker for injury (good for prognosis as well)

• NGAL (neutrophil gelatinase associated lipocalin) &

Cystatin C – both indicating kidney injury, also shown to

have prognostic value

ABG findings in PE

• pH= ↑

• PaO2= ↓

• PaCO2= ↓

• HCO3= Normal

• Aa gradient= Large

Aa gradient= PAO2- PaO2

Chest x-ray

• Mostly normal findings

• Done to exclude other pathology

• Pleural effusion/ Atelectatic bands

• Specific signs:- Hampton’s hump (in infarction)- Westermark sign

- Palla’s sign - Fleischner sign (in massive embolism or PHTN)

ECG findings in PE

• Normal sinus rhythm

• Sinus tachycardia

• Tall peaked T waves in V1- V4

• S1Q3T3 pattern: Not specific. Can be seen in any Cor pulmonale syndrome

• RBBB

S1Q3T3 pattern ECG

Echocardiogram in PE

- RV Strain

• An RV/LV ratio of >0.9 was shown to be and independent

predictive factor for HOSPITAL MORTALITY

• RV hypokinesia on baseline echo following PE with a ~40% higher

mortality rate

- Used also to detect TAPSE & Tricuspid Jet Velocity to

detect CTEPH

- TOE used to detect pulmonary artery emboli & its

branches

Doppler US

D-dimer in PE

• D-dimer is a type of Fibrin degradation product

• Can be raised due to a number of reasons

• Negative D-dimer rules out PE/DVT in 98% cases

• False positive D-dimer: infection, pregnancy, renal failure, post-operative

– Qualitative

• Bed side RBC agglutination test

• Low Specificity and Sensitivity

– “SimpliRED D-dimer”

– Quantitative

• Enzyme linked immunosorbent assay “Dimertest”

• Positive assay is > 500ng/ml

• VIDAS D-dimer, 2nd generation ELISA test

• Specificity decreases with age above 80 to 10% so

age-adjusted cut-off points are used for that

CTPA

Indications:

- Suspected PE

Contra-indications:- Renal failure

- Pregnancy

- Allergy to radio-contrast

Procedure:

- Radioactive iodine administered IV

- CT scan performed

Pitfalls of CTPA:

• Average radiation exposure is 12.4-31.8 mSV.

• This was estimated to increase the risk of breast cancer by 1.004 to 1.042 and lung cancer from 1.005 to 1.076.

• The excess risk of cancer for individuals over 55 would be less than 1%;

• In a young 20-year-old woman this would be estimated to increase the relative lifetime risk of breast or lung cancer by 1.7 to 5.5%.

(Hurwitz et al. 2007)

Multidetector helical CTPA• First line modality

• Cover all chest with high spatial resolution in one breath• Detect peripheral smaller emboli• Detect other pathologies• Detect RV strain (straightening or leftward bowing of IV

septum)

• Available

BUT• Needs expert in reading• Costy• Not portable

• Radiation Exposure

• # in renal failure and contrast allergy

Ventilation-perfusion scan

Indications:

- Renal failure

- Pregnancy

Procedure:

- Ventilation scan with Xenon inhalation

- Perfusion scan with Tc99m labelled radioactive dye infusion

- Scan V/Q

- Result: unmatched V/Q

Interpretation:

Ancillary TestAncillary Test

WBC Poor sensitivity and nonspecific (Can be as high

as 20,000 in some patients)

Hgb/Hct PTE does not alter count but if extreme, consider

polycythemia, a known risk factor

ESR Don’t get one, terrible test in regard to any

predictive value

DDXCondition Differentiating signs/symptoms

MI Retrosternal pressure radiating to the jaw, arm, or neck.Risk factors include long-standing hypertension, diabetes, or hypercholesterolaemia.

Pneumonia Cough, purulent sputum.Fever above 39.0°C generally higher than in PE.

Pneumothorax History of recent trauma to the chest.Decreased breath sounds unilaterally Hyperresonance on percussion of affected side.Deviation of the trachea away from the affected lung.

CHF, acute exacerbation

Orthopnoea, paroxysmal nocturnal dyspnoea,Increased bilateral lower extremity swelling.Diffuse crackles on pulmonary auscultation.Elevated jugular venous pressure.

Pericarditis Chest pain improves when sitting up and worsens when supine.

Tamponade, cardiac Beck's triad of hypotension, muffled heart sounds, and elevated jugular venous pressure

Panic disorder Sudden-onset anxiety, feeling faint, and palpitations.Recurrent, discrete period of intense fear/discomfort.

Treatment options• Symptomatic treatment:

– ABCD approach– Oxygen (FIO2 0.6–1.0 to maintain SaO2 93–98%) – Analgesia (morphine 5-10mg iv)– Lie patient flat to increase venous return. – Fluid challenge to optimize right heart filling. – Epinephrine infusion if circulation still compromised. – Mechanical ventilation may be needed. Gas exchange may

worsen due to loss of preferential shunting and decrease in cardiac output.

• Anticoagulation:– IV Heparin, S/C LMWH, Oral Warfarin

• IVC filter: If there is contra-indications for anti-coagulation

• Thrombolysis: tPA eg Alteplase, Tenectaplase

• Surgical procedures: Pulmonary embolectomy

• Massive PE: Thrombolysis/embolectomy

• Sub-massive PE: Strongly consider thrombolysis/

embolectomy but need to balance risk of bleeding

• Non-massive PE: Anticoagulation (treated at home)

Intermediate Risk (Submassive) PE

• Definition: Acute PE without systemic hypotension (systolic blood pressure 90 mm Hg) but with either:

-- RV dysfunction: Hypokinesia Or Dilatation: RV/LV diameter >0.9 on MDCT or Echo

-- BNP >90 pg/ml

-- Appropriate ECG Changes (RBBB, etc.)

-- Myocardial necrosis: Troponin I > 0.14ng/ml

• Intermediate Risk PE therapy:

-- ANTICOAGULATION (AC)- HEPARIN

AC therapy prevents further clot growth

Consider Single Drug NOAC’s for stable patients

-- Oxygen supplementation

-- Telemetry monitoring

High-Risk (Massive) PE

• Definition: Acute PE with:

– Cardiac arrest / hemodynamic instability

– Sustained hypotension (systolic blood pressure 90 mm Hg for at least 15 minutes OR requiring inotropic support not due to a secondary cause (arrhythmia, sepsis)

*Remember: The presence of “lots” of PE isn’t enough to call it “massive

• High-Risk PE therapy:

– Systemic Anticoagulation ASAP

– Supplemental oxygen for O2 sat <90%

– Admit to the intensive care unit: Significant hypoxemia, Hemodynamic compromise thrombolytic therapy

– Mechanical ventilation for respiratory failure

– For Hypotension: IVF, Vasopressor Support

AnticoagulationIV Heparin

– 80 units/kg bolus followed by – 18 units/kg infusion

• Monitor APTT 60-90 sec

• Side effects: – HITS (Heparin induced thrombocytopenia

syndrome): paradoxical hypercoagulable state leads to clots

– Bleeding

• Raschke Nomogram:Raschke Nomogram:

• Use of Heparin Before and After Thrombolysis:Use of Heparin Before and After Thrombolysis:

Low molecular weight Heparin (LMWH)

- Duration: 6 to 9 months

- Side effect: Low HITS

FondaparinuxFondaparinux• Anticoagulant pentasaccharide that specifically

inhibits activated factor X• By selectively binding to antithrombin, it

potentiates (about 300 times) the neutralization of factor Xa by antithrombin

• It does not cross-react with heparin-induced antibodies

• FDA has approved fondaparinux for initial treatment of acute PE and acute DVT as a bridge to oral anticoagulation with warfarin

Vitamin K antagonist

• Warfarin: – 5mg PO initial dose– Check regular INR 2-3

• Side effects:– Bleeding– Unusual bruises– Headache

Novel Oral Anticoagulants (NOACs)Novel Oral Anticoagulants (NOACs)

• Promise immediate onset of action and administration

in fixed doses without routine laboratory coagulation

monitoring but not used in severe renal impairment

• Few interactions, making them more “user friendly”

Dabigatran: direct thrombin inhibitor (150mg bid)

Rivaroxaban: factor Xa inhibitor (15mg bid 3wks 20mg o.d)

Apixaban: factor Xa inhibitor (10mg bid 1wk 5mg bid)

Edoxaban: factor Xa inhibitor (60mg o.d, 30mg if low cr.cl. Or

wt < 60 kg)

*N.B.:

The results of the trials (RE-COVER, RECORD-3, EINSTEIN-PE,

AMPLIFY, Hokusai-VTE) using NOACs in the treatment of VTE

indicate that these agents are non-inferior (in terms of efficacy) and

possibly safer (particularly in terms of major bleeding) than the

standard heparin/VKA regimen.

High TTR values were achieved under VKA treatment in all trials; on the

other hand, the study populations included relatively young patients,

very few of whom had cancer.

Recommendations for Initial Anticoagulation forRecommendations for Initial Anticoagulation for Acute PE Acute PE (AHA/ASC 2011, ACCP 2012) (AHA/ASC 2011, ACCP 2012)

• Therapeutic anticoagulation with SC LMWH, IV or SC UFH with

monitoring, unmonitored weight-based SC UFH, or SC

fondaparinux + VKA (till INR >2 for 24 hr) should be given to pts with

objectively confirmed PE and no # to anticoagulation (1B)

• Therapeutic parenteral anticoagulation during the diagnostic

workup should be given to pts with intermediate (if diag. delay >4hrs)

or high clinical probability of PE & no # to anticoagulation (2C)

• Therapeutic parenteral anticoagulation during the diagnostic

workup is not given in low probability (if diag. not delayed than 24 hrs)

(2C) Preferred than UFH except if # (renal impairment, with thrombolysis or can’t afford)

Optimal Duration of Anticoagulation Optimal Duration of Anticoagulation

ACCP 2012

According to bleeding risk (3Ms or Extended)

Thrombolysis

• Indications:

– Massive PE

– Sub-massive PE where risk of bleeding low (in RVD?!)

• Contraindications:

– Bleeding, recent stroke, HI, current GI bleeding,

bleeding PUD, surgery within 7 day, prolonged CPR

•Drugs:

(Most rapid)

• About administration About administration

Intravenous route

-- primary method of delivery

Rapid infusion

-- Shorter regimens may not only prove efficacious

but also reduce the risk of hemorrhagic

complications

Catheter-directed therapy

-- for massive PE, may induce major bleeding

• General guidelines for administration General guidelines for administration

before after

• Potential Benefits and HarmPotential Benefits and Harm

Potential benefits include

More rapid resolution of symptoms (eg, dyspnea, chest pain,

and psychological distress)

Stabilization of respiratory and cardiovascular function

without need for mechanical ventilation or vasopressor support

Reduction of RV damage

Improved exercise tolerance

Prevention of PE recurrence

Increased probability of survival

Potential harm includes

Disabling or fatal hemorrhage including intracerebral

hemorrhage

Increased risk of minor hemorrhage, resulting in prolongation

of hospitalization and need for blood product replacement

ACC/AHA & ACCP RecommendationsACC/AHA & ACCP Recommendations

Through Peripheral Vein is better than Pulmonary Artery Catheter

IVC filter• Indications:

- DVT with massive pulmonary embolus

- Recurrent PE not treatable with anticoagulation

- Absolute contra-indications for anti-coagulation

- Trauma patients

• Not used in:

- Patients with free-floating thrombi in the proximal veins

- Patients scheduled for systemic thrombolysis, surgical

embolectomy, or pulmonary thrombendarterectomy.

• Various inferior vena caval filtersVarious inferior vena caval filters::

A Greenfield filterA Greenfield filter

B Titanium Greenfield filter B Titanium Greenfield filter

C Simon-Nitinol filter C Simon-Nitinol filter

D LGM or Vena Tech filter D LGM or Vena Tech filter

E Amplatz filter E Amplatz filter

F Bird’s Nest filterF Bird’s Nest filter

G Günther filterG Günther filter

**Located mostly below renal veinsLocated mostly below renal veins

(Adapted from Becker et al.)

• Complications associated with IVC filterComplications associated with IVC filterEarly complications

• Device malposition (1.3%)

• Pneumothorax(0.02%),

• Hematoma (0.6%)

• Air embolism (0.2%)

• Inadvertent carotid artery

puncture (0.04%)

• Arteriovenous fistula

(0.02%)

Late complications

• Recurrent DVT (21%)

• IVC thrombosis (2% to

10%),

• IVC penetration (0.3%)

• Filter migration (0.3%)

• Recurrent PE (2-5%)

• Fatal PE (0.7%)

Recommendations on IVC Filters in the Recommendations on IVC Filters in the Setting of Acute PESetting of Acute PE

Catheter-Based InterventionsCatheter-Based Interventions• Performed as an alternative to thrombolysis When there are contraindications When emergency surgical thrombectomy is unavailable

or contraindicated Hybrid therapy that includes both catheter-based clot

fragmentation and local thrombolysis is an emerging strategy

• Goals of catheter-based therapy include Rapidly reducing pulmonary artery pressure, RV strain,

and pulmonary vascular resistance (PVR) Increasing systemic perfusion Facilitating RV recovery

• Categories of percutaneous intervention

Suction thrombectomy with aspiration catheters

Thrombus fragmentation with pigtail or balloon catheters

Rheolytic thrombectomy with hydrodynamic catheters

(saline jet or drug)

Rotational thrombectomy

Conventional catheter directed thrombolysis (drugs)

U/S accelerated thrombolysis with CDT (inc permeability)

Pharmaco-mechanical thrombolysis (combined technique)

• Catheter-directed therapyCatheter-directed therapy

Local delivery of streptokinase

-- Extensive lysis (by perfusion scan and pulmonary

arteriography at 12 to 24 hour follow-up)

Intrapulmonary versus peripheral alteplase

-- no advantage over the intravenous route

Direct delivery into clot

--Enhanced thrombolysis, relatively low doses (in an

animal model of PE)

-- Could prove advantageous over the intravenous route

• Side Effects (2%)

Death from worsening RV failure,

Distal embolization,

Pulmonary artery perforation with lung hemorrhage,

Systemic bleeding complications,

Pericardial tamponade,

Heart block or bradycardia,

Haemolysis,

Contrast-induced nephropathy, and

Puncture-related complications

Surgical EmbolectomySurgical Embolectomy

• When contraindications preclude thrombolysis

• Surgical excision of a right atrial thrombus

• Rescue patients whose condition is refractory to

thrombolysis

• Older case series suggest a mortality rate between 20%

and 30%

• In a more recent study, 47 patients underwent surgical

embolectomy in a 4-year period, with a 96% survival rate

Am Heart J 2011;134:479-87

Recommendations (AHA – ACCP)Recommendations (AHA – ACCP)

PE in Pregnancy• All three components of Virchow’s triad are affected during

pregnancy

• D-dimer has high negative predictive value. False positive result is common

• Ultrasonography of the legs is the initial investigation.

• V/Q scan is preferred technique

• CTPA can be done if V/Q is inconclusive

• Preferred treatment option: LMWH

• Warfarin is contraindicated

PE in Cancer

Prevention of PE

• Control of obesity

• Stop smoking

• Stockings

• Heparin: 5000 units/day SC bid or tid

• Enoxaprin: 40 mg/day SC

1 Hospitalization with medical illness

Enoxaparin 40 mg SC qd orDalteparin 5000 units SC qd orFondaparinux 2.5 mg SC qd (in patients with a heparin allergy such as heparin-induced thrombocytopenia) orGraduated compression stockings or intermittent pneumatic compression

2 General surgery Unfractionated heparin 5000 units SC bid or tid orEnoxaparin 40 mg SC qd orDalteparin 2500 or 5000 units SC qd

3 Major orthopedic surgery Warfarin (target INR 2 to 3) orEnoxaparin 30 mg SC bid orEnoxaparin 40 mg SC qd orDalteparin 2500 or 5000 units SC qd orFondaparinux 2.5 mg SC qdRivaroxaban 10 mg qd (in Canada and Europe)Dabigatran 220 mg bid (in Canada and Europe)

4 Oncologic surgery Enoxaparin 40 mg SC qd

5 Neurosurgery Unfractionated heparin 5000 units SC bid orEnoxaparin 40 mg SC qd andGraduated compression stockings or intermittent pneumatic compressionConsider surveillance lower extremity ultrasonography

6 Thoracic surgery Unfractionated heparin 5000 units SC tid andGraduated compression stockings or intermittent pneumatic compression

CTEPH

It is an important cause of pulmonary hypertension (Class IV-

mean PAP greater than 25 mm Hg) that either after PE is diagnosed

(0.1-9.1% in 2yrs after PE) or even without previous PE.

The only identifiable RFs for persistent pulmonary HTN: Age 70

years & Systolic PAP 50 mm Hg at the initial presentation ??

Unresolved residual thrombus becomes organized and fibrosed,

leading to ongoing obstruction to pulmonary blood flow.

Untreated, this leads to progressive pulmonary hypertension,

RV dysfunction, failure and death even on anticoagulation.

“Not a disease, but a

syndrome in which the

pressure in the pulmonary

circulation is raised”

Honeymoon Period

Progression of CTEPH

Acute or recurrent PTE in pulmonary arteries +/- inadequate anticoagulation

Organisation these thrombi

Occurence in situ thrombus due to slow blood flow in obstructed pulmonary arteries

Occurence of arteritis in non obstructed small distal pulmonary arteries (remodelling)

•

Increased PVR, pulmonary hypertensionCTEPH

1. Hypertensive remodeling of the patent arteries

2. Chronic arteriopathy of the obstructed branches

3. Plexiform lesions poor outcome after surgery

4. Development of pathological arterial shunts

5. In situ thrombosis

ACCORDING TO THE LENGTH OF THE DISEASE

Pathophysiology

Diagnosis of CTEPH

To confirm diagnosis, support ttt decisions &

Measure PVR pre and postop

Echo Probability of PHTN

Other Echo Findings

Echo signs from at least two different categories (A/B/C) from the list should be present to alter the level of echo probability of pulmonary hypertension.

Treatment of CTEPH

Operability/Inoperability (subjective):

• Functional class II–IV

• Surgical accessibility of thrombi in the main, lobar, or segmental

pulmonary arteries proximal cases

• Advanced age per se is no contraindication for surgery.

• There is no pulmonary vascular resistance threshold or measure of

RV dysfunction that absolutely precludes PEA.

• Balloon pulmonary angioplasty Vs Medical treatment

(anticoagulants, diuretics, O2) in inoperable cases or distal cases

• Drugs of PHTN tried in cases with microvascular abnormalities: in

inoperable cases or persistent PHTN after surgery.

PEA

BPA

Diagnosis of CTEPH with functional impairment and/or right heart failure

Surgically accessible obliteration of pulmonary vessels

Estimated reduction in PVR>50%

Advanced pulmonary vascular diseasePVR disproportionately elevated

Estimated reduction in PVR <50%

Severe comorbiditiesPrecluding surgery

Severe comorbiditiesPrecluding surgery

PEAMedicalTherapy

Lung transplant

Persistent symptomatic PHT Persistent symptomatic PHT

No Yes No

Circulation 2006;113;2011-2020

Anticoagulation

Yes

Humbert M et al. N Engl J Med. 2004;351:1425-1436.

Targets for Current or Emerging TherapiesTargets for Current or Emerging Therapies

Big EndothelinBig Endothelin

Endothelin-Endothelin-convertingconverting

EnzymeEnzyme

EndothelinEndothelinReceptor AReceptor A

EndothelinEndothelinReceptor BReceptor B

VasoconstrictionVasoconstrictionandand

ProliferationProliferation

EndothelinReceptor

Antagonists

Endothelin-1Endothelin-1

Endothelin PathwayEndothelin Pathway

ArginineArginine

Nitric OxideNitric OxideSynthaseSynthase

VasodilatationVasodilatationandand

AntiproliferationAntiproliferation

Nitric OxideNitric Oxide

cGMPcGMP ExogenousNitric Oxide

Phosphodiesterase Type-5Phosphodiesterase Type-5

PhosphodiesteraseType-5 Inhibitors

Nitric Oxide PathwayNitric Oxide Pathway

Arachidonic AcidArachidonic Acid

ProstacyclinProstacyclinSynthaseSynthase

VasodilatationVasodilatationandand

AntiproliferationAntiproliferation

ProstacyclinProstacyclin

cAMPcAMP

ProstacyclinProstacyclinDerivativesDerivatives

ProstacyclinDerivatives

Prostacyclin PathwayProstacyclin Pathway

Guanylate cyclase stimulator

(Adempus)

2.5mg tds